skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration

Original Research

(2160) Views  (585) Full article downloads

Authors: R Prince Davis, Amy C Schefler, Timothy G Murray

Published Date June 2010 Volume 2010:4 Pages 703 - 707
DOI: http://dx.doi.org/10.2147/OPTH.S10008

R Prince Davis, Amy C Schefler, Timothy G Murray

Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USA

Purpose: To report the outcomes of same-day, bilateral intravitreal anti-vascular endothelial growth factor (VEGF) therapy for a consecutive series of patients treated for exudative age-related macular degeneration (ARMD).

Methods: A consecutive series of 254 eyes of 127 patients received bilateral, same-day anti-VEGF injections of either bevacizumab or ranibizumab between January 1, 2007 and July 1, 2008 and the outcomes were assessed. Approval was obtained from the Institutional Review Board at the University of Miami Miller School of Medicine.

Results: Bilateral, same-day anti-VEGF injections were well tolerated in all patients receiving the therapy. Indication for injection was exudative macular degeneration in all patients. The incidence of adverse effects was low, with only four events reported, none of which were serious.

Conclusions: In this study, bilateral anti-VEGF injections performed on the same day were preferred over staggered injections and were well tolerated by patients. No major systemic or ocular adverse events were noted, despite the presence of risk factors in a subset of patients. Given that there are serious, albeit rare, complications following anti-VEGF injection, further study with a larger number of patients will be necessary to definitively prove the safety of this treatment modality.

Keywords: visual acuity, same-day treatment, bevacizumab, ranibizumab






 

Other articles by Professor Timothy G Murray

Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors
Can children undergoing ophthalmologic examinations under anesthesia be safely anesthetized without using an IV line?
Clinical imaging and high-resolution ultrasonography in melanocytoma management
Evaluation of economic efficiencies in clinical retina practice: activity-based cost analysis and modeling to determine impacts of changes in patient management
Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review
Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors


Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of endophthalmitis
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Case of endophthalmitis following intravitreal injections of bevacizumab
A protocol for the retina surgeon’s safe initial intravitreal injections
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy